3Q EARNINGS: Merck's Januvia sales fall, quarterly results miss targets
This article was originally published in Scrip
Merck & Co said sales of its largest drug, the diabetes treatment Januvia, fell in a quarter marked by lower than expected profit and revenue plus write offs for job cuts.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.